Inhibition of NF-κB Signaling by Quinacrine Is Cytotoxic to Human Colon Carcinoma Cell Lines and Is Synergistic in Combination with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) or Oxaliplatin

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation

(2014) D Hind et al.   HEALTH TECHNOLOGY ASSESSMENT

Phase I Study of Capecitabine and Oxaliplatin in Combination With the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors

(2009) Steven J. Cohen et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

(2009) H. A. Wakelee et al.   ANNALS OF ONCOLOGY

Bortezomib paradigm shift in myeloma

(2009) D. J. McConkey   BLOOD

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Antitumor Activity of Gemcitabine and Oxaliplatin Is Augmented by Thymoquinone in Pancreatic Cancer

(2009) Sanjeev Banerjee et al.   CANCER RESEARCH

Constitutive NF- B Activation in Colorectal Carcinoma Plays a Key Role in Angiogenesis, Promoting Tumor Growth

(2009) K. Sakamoto et al.   CLINICAL CANCER RESEARCH

Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts

(2009) Ling Xu et al.   FEBS LETTERS

Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis

(2009) Ronald Koschny et al.   JOURNAL OF NEURO-ONCOLOGY

Nuclear Factor-κB Activation: From Bench to Bedside

(2008) Gautam Sethi et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-κB inhibition

(2008) Johannes U. Ammann et al.   INTERNATIONAL JOURNAL OF CANCER

To kill a tumor cell: the potential of proapoptotic receptor agonists

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL INVESTIGATION

Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor- B Transcription and Evasion of Apoptosis

(2008) C. Wilson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Imatinib resistance in multidrug-resistant K562 human leukemic cells

(2008) Yanina Assef et al.   LEUKEMIA RESEARCH

Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells

(2008) T R Wilson et al.   ONCOGENE

p53-Mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells

(2008) F Toscano et al.   ONCOGENE

Up-regulation of a cellular protein at the translational level by a retrovirus

(2008) F. K. Yoshimura et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA